Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.